Resource Summary Report

Generated by NIF on Sep 18, 2026

LN-18

RRID:CVCL_0392
Type: Cell Line

Proper Citation

RRID:CVCL_0392

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0392

Proper Citation: RRID:CVCL_0392

Description: Cell line LN-18 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: PMID:7211194, PMID:7693337, PMID:7732013, PMID:8509230, PMID:9842975, PMID:10416987, PMID:14614447, PMID:14655754, PMID:17595512, PMID:21406405, PMID:22460905, PMID:22570425, PMID:25485619, PMID:25877200, PMID:25894527, PMID:26496030, PMID:26589293, PMID:27397505, PMID:30894373, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LN-18

Synonyms: LN 18, LN18, LN018

Cross References: BTO:BTO_0002005, CLO:CLO_0007362, EFO:EFO_0006636, MCCL:MCC:0000287, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2610, BCRJ:0420, BioGRID_ORCS_Cell_line:410, BioSample:SAMN03471122, BioSample:SAMN10988197, cancercelllines:CVCL_0392, Cell_Model_Passport:SIDM00685, ChEMBL-Cells:CHEMBL4295405, ChEMBL-Targets:CHEMBL4296458, CLS:305822,

Cosmic:849858, Cosmic:1746957, Cosmic:1995484, Cosmic:2302322, Cosmic:2367489, Cosmic:2491101, Cosmic-CLP:1240168, DepMap:ACH-000819, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240168, GEO:GSM326196, GEO:GSM397661, GEO:GSM397662, GEO:GSM887269, GEO:GSM888344, GEO:GSM1374620, GEO:GSM1670048, IARC_TP53:2570, LiGeA:CCLE_635, LINCS_LDP:LCL-1353, Lonza:1681, PharmacoDB:LN18_839_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_0392, PubChem_Cell_line:CVCL_0392, Wikidata:Q54902768

ID: CVCL_0392

Record Creation Time: 20220427T220730+0000

Record Last Update: 20260913T004746+0000

Ratings and Alerts

No rating or validation information has been found for LN-18.

No alerts have been found for LN-18.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Meena D, et al. (2026) Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology. Journal of cellular physiology, 241(3), e70163.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. Molecular cell, 86(8), 1546.

Rurka P, et al. (2026) A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. Molecular oncology.

Bien-M??ller S, et al. (2025) The protease-activated receptors are expressed in glioblastoma and differentially modulate adherent versus stem-like growth of LN-18 GBM cells. Frontiers in oncology, 15, 1582996.

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex. Cancer discovery, 15(12), 2505.

Lee YB, et al. (2024) Function of a complex of p-Y42 RhoA GTPase and pyruvate kinase M2 in EGF signaling pathway in glioma cells. Journal of neurochemistry.

Hesse J, et al. (2024) Intercellular crosstalk shapes purinergic metabolism and signaling in cancer cells. Cell reports, 43(1), 113643.

Sallbach J, et al. (2024) The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 181, 117634.

Tang M, et al. (2024) Inhibition of thioredoxin reductase 1 sensitizes glucose-starved glioblastoma cells to disulfidptosis. Cell death and differentiation.

Leszczynska KB, et al. (2024) H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells. Cell reports, 43(2), 113707.

Tan IL, et al. (2023) Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis. Cell reports, 42(11), 113339.

Kim JY, et al. (2023) Jagged1 intracellular domain/SMAD3 complex transcriptionally regulates TWIST1 to drive glioma invasion. Cell death & disease, 14(12), 822.

Ham SW, et al. (2023) Annexin A2 Stabilizes Oncogenic JAG1 Intracellular Domain by Inhibiting Proteasomal Degradation in Glioblastoma Cells. International journal of molecular sciences, 24(19).

Nguyen TT, et al. (2023) Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG. Molecular oncology, 17(9), 1744.

Patrick S, et al. (2023) Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics. Cellular signalling, 109, 110738.

Zhang B, et al. (2022) Targeting BCAT1 Combined with ??-Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma. Cancer research, 82(13), 2388.

Shi Z, et al. (2022) Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas. Molecular cell, 82(20), 3919.

Han W, et al. (2022) Targeting HOTAIRM1 ameliorates glioblastoma by disrupting mitochondrial oxidative phosphorylation and serine metabolism. iScience, 25(8), 104823.

Kim EJ, et al. (2022) The oncogenic JAG1 intracellular domain is a transcriptional cofactor that acts in concert with DDX17/SMAD3/TGIF2. Cell reports, 41(8), 111626.